Trial Profile

A Phase I/III, Multi-center, Randomized, Double-blind Study of BAT3306 Plus Chemotherapy Versus Keytruda Plus Chemotherapy to Evaluate Pharmacokinetics, Efficacy, and Safety in Participants With Stage IV Non-squamous Non-small Cell Lung Cancer.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 3306 (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Pembrolizumab
Indications Non-small cell lung cancer
Focus Pharmacokinetics; Registrational
Sponsors Bio-Thera Solutions

25 Jul 2024 According to a Bio-Thera Solutions media release, the company announced that dosing has recently begun in an integrated Phase I / Phase III clinical study for BAT3306, a proposed biosimilar of Keytruda (pembrolizumab).
25 Jul 2024 Status changed from not yet recruiting to recruiting, according to a Bio-Thera Solutions media release.
01 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com